Free Trial

Quanterix (QTRX) Competitors

Quanterix logo
$3.10 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$3.10 0.00 (-0.16%)
As of 06/12/2026 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QTRX vs. SIBN, CTKB, OPTX, LAB, and PRE

Should you buy Quanterix stock or one of its competitors? MarketBeat compares Quanterix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quanterix include SiBone (SIBN), Cytek Biosciences (CTKB), Syntec Optics (OPTX), Standard BioTools (LAB), and Prenetics Global (PRE).

How does Quanterix compare to SiBone?

SiBone (NASDAQ:SIBN) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

SiBone presently has a consensus target price of $23.00, suggesting a potential upside of 49.16%. Quanterix has a consensus target price of $4.00, suggesting a potential upside of 29.03%. Given SiBone's stronger consensus rating and higher possible upside, equities analysts clearly believe SiBone is more favorable than Quanterix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SiBone
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Quanterix
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

SiBone has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

SiBone has higher revenue and earnings than Quanterix. SiBone is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SiBone$200.93M3.40-$18.90M-$0.39N/A
Quanterix$138.90M1.05-$107.15M-$2.36N/A

SiBone has a net margin of -8.10% compared to Quanterix's net margin of -71.86%. SiBone's return on equity of -9.56% beat Quanterix's return on equity.

Company Net Margins Return on Equity Return on Assets
SiBone-8.10% -9.56% -7.06%
Quanterix -71.86%-23.92%-17.66%

In the previous week, Quanterix had 3 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Quanterix and 3 mentions for SiBone. SiBone's average media sentiment score of 0.60 beat Quanterix's score of 0.33 indicating that SiBone is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SiBone
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Quanterix
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

98.1% of SiBone shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 3.9% of SiBone shares are held by insiders. Comparatively, 1.5% of Quanterix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

SiBone beats Quanterix on 13 of the 16 factors compared between the two stocks.

How does Quanterix compare to Cytek Biosciences?

Quanterix (NASDAQ:QTRX) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

86.5% of Quanterix shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Quanterix has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Cytek Biosciences has higher revenue and earnings than Quanterix. Cytek Biosciences is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quanterix$138.90M1.05-$107.15M-$2.36N/A
Cytek Biosciences$204.17M2.50-$66.54M-$0.57N/A

Quanterix presently has a consensus target price of $4.00, suggesting a potential upside of 29.03%. Cytek Biosciences has a consensus target price of $5.69, suggesting a potential upside of 43.62%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Quanterix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quanterix
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Cytek Biosciences
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Cytek Biosciences has a net margin of -36.25% compared to Quanterix's net margin of -71.86%. Cytek Biosciences' return on equity of -10.07% beat Quanterix's return on equity.

Company Net Margins Return on Equity Return on Assets
Quanterix-71.86% -23.92% -17.66%
Cytek Biosciences -36.25%-10.07%-7.56%

In the previous week, Quanterix had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 6 mentions for Quanterix and 3 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat Quanterix's score of 0.33 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quanterix
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cytek Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Cytek Biosciences beats Quanterix on 13 of the 16 factors compared between the two stocks.

How does Quanterix compare to Syntec Optics?

Quanterix (NASDAQ:QTRX) and Syntec Optics (NASDAQ:OPTX) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

In the previous week, Quanterix and Quanterix both had 6 articles in the media. Quanterix's average media sentiment score of 0.33 beat Syntec Optics' score of 0.19 indicating that Quanterix is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quanterix
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Syntec Optics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Quanterix currently has a consensus price target of $4.00, suggesting a potential upside of 29.03%. Given Quanterix's stronger consensus rating and higher probable upside, equities analysts plainly believe Quanterix is more favorable than Syntec Optics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quanterix
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Syntec Optics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Syntec Optics has lower revenue, but higher earnings than Quanterix. Syntec Optics is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quanterix$138.90M1.05-$107.15M-$2.36N/A
Syntec Optics$28.08M19.01-$1.79M-$0.08N/A

Quanterix has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Syntec Optics has a beta of -0.82, suggesting that its stock price is 182% less volatile than the broader market.

86.5% of Quanterix shares are held by institutional investors. 1.5% of Quanterix shares are held by insiders. Comparatively, 0.8% of Syntec Optics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Syntec Optics has a net margin of -10.95% compared to Quanterix's net margin of -71.86%. Quanterix's return on equity of -23.92% beat Syntec Optics' return on equity.

Company Net Margins Return on Equity Return on Assets
Quanterix-71.86% -23.92% -17.66%
Syntec Optics -10.95%-30.86%-12.35%

Summary

Quanterix beats Syntec Optics on 9 of the 14 factors compared between the two stocks.

How does Quanterix compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Quanterix had 1 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for Quanterix and 5 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.39 beat Quanterix's score of 0.33 indicating that Standard BioTools is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Standard BioTools
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Quanterix
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Standard BioTools has a net margin of 73.46% compared to Quanterix's net margin of -71.86%. Standard BioTools' return on equity of -8.18% beat Quanterix's return on equity.

Company Net Margins Return on Equity Return on Assets
Standard BioTools73.46% -8.18% -6.43%
Quanterix -71.86%-23.92%-17.66%

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 26.8% of Standard BioTools shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Standard BioTools currently has a consensus target price of $1.35, suggesting a potential upside of 52.08%. Quanterix has a consensus target price of $4.00, suggesting a potential upside of 29.03%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than Quanterix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Standard BioTools
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Quanterix
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Standard BioTools has higher earnings, but lower revenue than Quanterix. Quanterix is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Standard BioTools$86.26M4.02-$74.90M$0.204.44
Quanterix$138.90M1.05-$107.15M-$2.36N/A

Standard BioTools has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Summary

Standard BioTools beats Quanterix on 11 of the 14 factors compared between the two stocks.

How does Quanterix compare to Prenetics Global?

Prenetics Global (NASDAQ:PRE) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Prenetics Global has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

In the previous week, Prenetics Global had 8 more articles in the media than Quanterix. MarketBeat recorded 14 mentions for Prenetics Global and 6 mentions for Quanterix. Prenetics Global's average media sentiment score of 0.61 beat Quanterix's score of 0.33 indicating that Prenetics Global is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prenetics Global
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Quanterix
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Prenetics Global has higher earnings, but lower revenue than Quanterix. Prenetics Global is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prenetics Global$120.07M3.04-$37.71M-$4.58N/A
Quanterix$138.90M1.05-$107.15M-$2.36N/A

Prenetics Global has a net margin of -62.45% compared to Quanterix's net margin of -71.86%. Prenetics Global's return on equity of -20.33% beat Quanterix's return on equity.

Company Net Margins Return on Equity Return on Assets
Prenetics Global-62.45% -20.33% -15.42%
Quanterix -71.86%-23.92%-17.66%

Prenetics Global presently has a consensus target price of $32.33, indicating a potential upside of 49.48%. Quanterix has a consensus target price of $4.00, indicating a potential upside of 29.03%. Given Prenetics Global's stronger consensus rating and higher probable upside, equities analysts plainly believe Prenetics Global is more favorable than Quanterix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prenetics Global
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Quanterix
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Prenetics Global beats Quanterix on 11 of the 16 factors compared between the two stocks.

Get Quanterix News Delivered to You Automatically

Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QTRX vs. The Competition

MetricQuanterixMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$146.04M$8.31B$6.52B$12.05B
Dividend YieldN/A2.50%2.67%5.66%
P/E Ratio-1.3115.6424.0024.42
Price / Sales1.057.06514.65112.54
Price / CashN/A17.4427.4837.92
Price / Book0.493.6210.696.82
Net Income-$107.15M$224.06M$3.57B$337.56M
7 Day Performance-0.96%-1.40%0.61%1.16%
1 Month Performance12.73%4.39%1.56%3.16%
1 Year Performance-48.84%-0.88%25.44%30.60%

Quanterix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QTRX
Quanterix
3.054 of 5 stars
$3.10
flat
$4.00
+29.0%
-48.8%$146.04M$138.90MN/A460
SIBN
SiBone
2.3302 of 5 stars
$14.97
-1.0%
$23.00
+53.6%
-11.5%$670.56M$200.93MN/A350
CTKB
Cytek Biosciences
2.3221 of 5 stars
$4.04
-1.2%
$5.69
+40.8%
+23.0%$528.20M$204.17MN/A500
OPTX
Syntec Optics
0.1739 of 5 stars
$11.91
+4.9%
N/A+867.2%$457.18M$28.08MN/A3
LAB
Standard BioTools
2.7452 of 5 stars
$0.80
-30.2%
$1.35
+68.1%
-15.5%$448.92M$86.26M4.02620

Related Companies and Tools


This page (NASDAQ:QTRX) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners